Recently, Xinhua Pharmaceutical's Ambroxol Oral Solution was approved by the National Medical Products Administration and obtained the "Drug Registration Certificate".
Ambroxol hydrochloride oral solution is a compound preparation composed of ambroxol hydrochloride and clenbuterol hydrochloride, with a specification of 100ml: 150mg of ambroxol hydrochloride and 100μg of clenbuterol hydrochloride. Ambroxol hydrochloride is a mucolytic agent that increases the secretion of serous glands in the respiratory mucosa, reduces mucus secretion, lowers sputum viscosity, promotes the secretion of pulmonary surfactant, and increases bronchial ciliary movement, making sputum easier to cough up. Clenbuterol hydrochloride is a selective β-receptor agonist that relaxes bronchial smooth muscle, enhances ciliary movement, dissolves mucus, and promotes sputum expectoration. Ambroxol hydrochloride oral solution is used to treat cough, thick sputum, difficulty in expectoration, and wheezing caused by acute and chronic respiratory diseases (such as acute and chronic bronchitis, emphysema, etc.), and has a triple effect of relieving cough, expectoration, and relieving asthma. The combination of ambroxol hydrochloride and clenbuterol hydrochloride works synergistically to comprehensively improve respiratory infection symptoms such as cough, difficulty in expectorating phlegm, and wheezing.
Ambroxol oral solution is currently a leading brand of pediatric respiratory medications in China, and is also widely used in respiratory and geriatric departments. Its dosage is clearly defined and its dosage gradient is detailed, providing safe and effective medication guidance for both pediatric and adult patients, making it a first-line treatment for respiratory diseases. According to relevant statistics, sales of ambroxol oral solution in Chinese public medical institutions reached approximately RMB 740 million in 2024.
Respiratory medications are a key strategic product for Xinhua Pharmaceutical, which boasts classic cough suppressants such as compound glycyrrhiza tablets, compound theophylline-ephedrine tablets, theophylline-ephedrine tablets, aminophylline tablets, aminophylline injection, ephedrine-diphenhydramine tablets, and theophylline sustained-release tablets. In recent years, the company has also obtained approvals for products such as ambroxol oral solution, bromhexine hydrochloride tablets, levosalbutamol hydrochloride nebulized inhalation solution, and dihydroxypropyl theophylline injection. The recent approval of ambroxol-terbutaline oral solution further enriches the company's product pipeline, enhances its overall competitiveness in the respiratory medication field, and provides patients with more precise and safer treatment options.

https://bydrug.pharmcube.com/news/detail/5ded14ba5823c470020e42080275dccd